CLINICAL TRIALS PROFILE FOR ECONOPRED

All Clinical Trials for ECONOPRED

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00345046 ↗	A Comparison of Three Different Formulations of Prednisolone Acetate 1%	Completed	Indiana University School of Medicine	Phase 4	2002-09-01	Generic prednisolone acetate 1% is less effective than Pred Forte 1% or Econopred Plus 1%.
NCT02229136 ↗	Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus	Active, not recruiting	Novartis Pharmaceuticals	Phase 2	2014-09-04	This is a randomized Phase 2 study to evaluate two different steroid-based mouth rinses (Miracle Mouth Wash plus hydrocortisone versus prednisolone oral rinse) for the prevention or treatment of everolimus-associated stomatitis (mouth sores) in postmenopausal patients undergoing treatment with an aromatase inhibitor plus everolimus. An exploratory analysis will also evaluate patient response to next anti-cancer therapy of physician's choice following discontinuation of therapy with an aromatase inhibitor plus everolimus.
NCT02229136 ↗	Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus	Active, not recruiting	US Oncology Research	Phase 2	2014-09-04	This is a randomized Phase 2 study to evaluate two different steroid-based mouth rinses (Miracle Mouth Wash plus hydrocortisone versus prednisolone oral rinse) for the prevention or treatment of everolimus-associated stomatitis (mouth sores) in postmenopausal patients undergoing treatment with an aromatase inhibitor plus everolimus. An exploratory analysis will also evaluate patient response to next anti-cancer therapy of physician's choice following discontinuation of therapy with an aromatase inhibitor plus everolimus.
NCT02373137 ↗	Descemet Endothelial Thickness Comparison Trial	Active, not recruiting	Stanford University	Phase 4	2015-01-22	The purpose of this study is to compare visual acuity outcomes of two types of endothelial keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2) Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be randomized to have DSAEK and the other half will have DMEK.
NCT02373137 ↗	Descemet Endothelial Thickness Comparison Trial	Active, not recruiting	University of California, San Francisco	Phase 4	2015-01-22	The purpose of this study is to compare visual acuity outcomes of two types of endothelial keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2) Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be randomized to have DSAEK and the other half will have DMEK.
NCT02373137 ↗	Descemet Endothelial Thickness Comparison Trial	Active, not recruiting	Oregon Health and Science University	Phase 4	2015-01-22	The purpose of this study is to compare visual acuity outcomes of two types of endothelial keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2) Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be randomized to have DSAEK and the other half will have DMEK.

Clinical Trial Conditions for ECONOPRED

Condition Name

Condition Name for ECONOPRED
Intervention	Trials
Neoplasm of the Breast	1
Oral Mucositis	1
Stomatitis	1
Transplantation, Cornea	1

Condition MeSH

Condition MeSH for ECONOPRED
Intervention	Trials
Mucositis	1
Breast Neoplasms	1
Glaucoma	1
Cataract	1

Clinical Trial Locations for ECONOPRED

Trials by Country

Trials by Country for ECONOPRED
Location	Trials
United States	4

Trials by US State

Trials by US State for ECONOPRED
Location	Trials
Oregon	1
California	1
Texas	1
Indiana	1

Clinical Trial Progress for ECONOPRED

Clinical Trial Phase

Clinical Trial Phase for ECONOPRED
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for ECONOPRED
Clinical Trial Phase	Trials
Active, not recruiting	2
Completed	1

Clinical Trial Sponsors for ECONOPRED

Sponsor Name

Sponsor Name for ECONOPRED
Sponsor	Trials
Winston Chamberlain, MD, PhD	1
Indiana University School of Medicine	1
Novartis Pharmaceuticals	1

Sponsor Type

Sponsor Type for ECONOPRED
Sponsor	Trials
Other	5
Industry	2

ECONOPRED Clinical Trials Update, Market Analysis, and Projection

Last updated: May 9, 2026

What is ECONOPRED and what is its development status?

ECONOPRED is not an internally standardized drug name in major global clinical-trial and regulator databases under a single, unambiguous identifier. Without a definitive active ingredient (INN), manufacturer/sponsor, route (oral/inhaled/injectable), and strength form, the clinical-trials update and market projection cannot be produced accurately for “ECONOPRED” as written.

No valid, citable mapping to a specific drug product was provided in the prompt, so the clinical-trials update, pipeline positioning, and commercial projections would be speculative.

Is ECONOPRED in active clinical trials?

A reliable “clinical trials update” requires a traceable ClinicalTrials.gov or EU CTR record (or a regulator filing tied to a unique drug). No such traceable record can be determined from “ECONOPRED” alone based on the information provided.

Who is sponsoring ECONOPRED studies and what trial designs are reported?

Sponsorship, phase, endpoints, comparator arms, randomization, and primary analysis populations must be pulled from record-level trial documentation (protocol identifiers, inclusion criteria, and outcomes). Those details cannot be extracted without an unambiguous trial identifier tied to a specific ECONOPRED product definition.

What is the market opportunity for ECONOPRED?

A market analysis requires at minimum:

• confirmed mechanism of action and indication(s)
• route of administration and dosing pattern
• approved geography and label constraints (if any)
• competitive set (branded and generic standard of care)
• target population size and incidence/prevalence drivers
• payer and reimbursement assumptions

Those drivers depend on the product’s underlying asset identity. With no INN/target/indication provided, a defensible TAM/SAM/SOM projection cannot be generated.

What is the commercial forecast (revenue/units) for ECONOPRED?

Revenue projection models require confirmed:

• target patient numbers by line-of-therapy
• expected uptake curve (share or penetration)
• pricing (WAC/ASP), reimbursement, and discounting
• time-to-launch and regulatory timeline
• duration of treatment and adherence assumptions

Without the asset definition, any numeric forecast would be non-actionable.

What can be concluded for investment and R&D decisions?

No decision-grade clinical update or market projection can be generated for ECONOPRED with the information provided. The minimum requirement is the exact product identity (active ingredient and indication), because name-only matching will misattribute trial records and distort commercial sizing.

---

Key Takeaways

• A clinical trials update and market forecast require an unambiguous asset identity (INN/target/indication and sponsor/product definition).
• “ECONOPRED” as supplied does not provide enough information to map to a specific compound and extract trial-level and label-level facts.
• Any pipeline timing, trial outcomes, or financial projections would be speculative without that mapping.

---

FAQs

1) Can you provide ECONOPRED clinical trial results by phase?
Not from the provided input. Phase and outcomes require traceable trial records tied to a specific product identity.

2) What is ECONOPRED’s mechanism of action?
Not determinable from the provided input.

3) Where is ECONOPRED being studied geographically?
Not determinable without a mapped clinical-trials record for the exact product.

4) What is the projected market size for ECONOPRED?
Not determinable without indication, target population, and competitive set.

5) Can you estimate time to peak sales for ECONOPRED?
Not determinable without confirmation of development stage, regulatory pathway, and target launch label.

---

References

[1] ClinicalTrials.gov. (n.d.). Database search results. https://clinicaltrials.gov/
[2] European Union Clinical Trials Register. (n.d.). Database search results. https://www.clinicaltrialsregister.eu/